PetVivo (NASDAQ:PETV) and GBS (NYSE:GBS) Financial Review

Earnings & Valuation

This table compares PetVivo and GBS”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetVivo	$1.05 million	34.67	-$10.95 million	($0.40)	-2.70
GBS	N/A	N/A	-$8.31 million	($0.56)	-1.15

GBS has lower revenue, but higher earnings than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than GBS, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

PetVivo has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, GBS has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.

Profitability

This table compares PetVivo and GBS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PetVivo	-902.82%	-4,813.07%	-281.78%
GBS	N/A	-85.64%	-54.42%

Institutional and Insider Ownership

24.5% of PetVivo shares are held by institutional investors. Comparatively, 2.8% of GBS shares are held by institutional investors. 10.8% of PetVivo shares are held by insiders. Comparatively, 0.3% of GBS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

GBS beats PetVivo on 6 of the 10 factors compared between the two stocks.

About PetVivo

PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.

About GBS

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.